LPL and its specific physiological activator,
apolipoprotein C-II (
apoC-II), regulate the hydrolysis of
triglycerides (TGs) from circulating TG-rich
lipoproteins. Previously, we developed a skeletal muscle-specific LPL transgenic mouse that had lower plasma TG levels.
ApoC-II transgenic mice develop
hypertriglyceridemia attributed to delayed clearance. To investigate whether overexpression of LPL could correct this
apoC-II-induced
hypertriglyceridemia, mice with overexpression of human
apoC-II (CII) were cross-bred with mice with two levels of muscle-specific human LPL overexpression (LPL-L or LPL-H). Plasma TG levels were 319 +/- 39 mg/dl in CII mice and 39 +/- 5 mg/dl in wild-type mice. Compared with CII mice,
apoC-II transgenic mice with the higher level of LPL overexpression (CIILPL-H) had a 50% reduction in plasma TG levels (P = 0.013). Heart LPL activity was reduced by approximately 30% in mice with the human
apoC-II transgene, which accompanied a more modest 10% decrease in total LPL
protein. Overexpression of human LPL in skeletal muscle resulted in dose-dependent reduction of plasma TGs in
apoC-II transgenic mice. Along with plasma
apoC-II concentrations, heart and skeletal muscle LPL activities were predictors of plasma TGs. These data suggest that mice with the human
apoC-II transgene may have alterations in the expression/activity of endogenous LPL in the heart. Furthermore, the decrease of LPL activity in the heart, along with the inhibitory effects of excess
apoC-II, may contribute to the
hypertriglyceridemia observed in
apoC-II transgenic mice.